+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Drug Delivery System Market - Global Forecast to 2030- Product Image
Targeted Drug Delivery System Market - Global Forecast to 2030- Product Image
Sale

Targeted Drug Delivery System Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336727
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Drug Delivery System Market grew from USD 9.61 billion in 2024 to USD 11.41 billion in 2025. It is expected to continue growing at a CAGR of 18.35%, reaching USD 26.43 billion by 2030.

Targeted drug delivery systems represent a paradigm shift in therapeutic strategies, offering the promise of higher efficacy, reduced systemic toxicity, and personalized treatment modalities. Fueled by breakthroughs in nanotechnology, molecular biology, and formulation science, these systems allow active pharmaceutical ingredients to reach specific disease sites with unprecedented precision. This introduction outlines the critical drivers, regulatory considerations, and collaborative models defining the current landscape.

Innovations in carrier design have enabled controlled release, enhanced bioavailability, and improved patient compliance. At the same time, evolving regulatory frameworks are streamlining pathways for complex formulations while maintaining rigorous safety and efficacy standards. Strategic alliances among academic institutions, biotechnology firms, and established pharmaceutical companies are accelerating translation from bench to bedside.

In this executive summary, we explore the transformative shifts reshaping targeted delivery, assess the repercussions of recent trade policies, dissect granular segmentation insights, highlight regional and competitive dynamics, and offer actionable recommendations. Our goal is to equip decision-makers with a clear, authoritative view of opportunities and challenges, supporting informed strategies that drive sustainable growth and therapeutic innovation.

Transformative Shifts Reshaping Targeted Drug Delivery Technologies

Nanotechnology integration, precision medicine initiatives, and advanced manufacturing techniques are collectively driving transformative shifts across the targeted drug delivery landscape. Converging disciplines are enabling multifunctional carriers that combine therapeutic payloads with imaging agents, ushering in a new era of theranostics.

Regulatory agencies are adapting to novel modalities by introducing flexible frameworks that encourage early dialogue, predictive safety assessments, and adaptive trial designs. This regulatory evolution is fostering an environment where complex formulations can progress more rapidly through development cycles. Meanwhile, digital platforms and artificial intelligence tools are optimizing formulation parameters and predicting in vivo behavior, reducing reliance on trial‐and‐error methods.

Partnership models are also evolving: collaborations between specialized nanomaterial providers and clinical research organizations are streamlining preclinical testing, while alliances with contract manufacturing organizations ensure scalable, cost‐effective production. In parallel, patient advocacy groups and payers are demanding evidence of real‐world effectiveness, making post‐approval surveillance and health economics studies integral to commercialization strategies.

Together, these shifts are redefining what is possible in targeted delivery, positioning the industry to address complex diseases with higher precision and generate compelling value propositions for all stakeholders.

Assessing the Cumulative Impact of US Tariffs in 2025 on Supply Chains and Costs

In 2025, updated tariffs on raw materials and specialized components have significantly influenced the cost structure of targeted delivery systems. Many carriers rely on imported metals, lipids, polymers and biologics; the new duties on gold and silica nanoparticles, lipid excipients and advanced polymers have elevated input costs by double‐digit percentages.

Supply chain disruptions-exacerbated by these levies-have prompted lead times to extend, requiring companies to adopt resilient sourcing strategies and increase onshore manufacturing capabilities. To mitigate margin erosion, organizations are negotiating long‐term supplier agreements, exploring alternative materials that deliver comparable performance, and accelerating efforts to qualify domestic vendors.

At the same time, research institutions are reassessing procurement plans for reagents and instrumentation, factoring in higher import costs when budgeting preclinical studies. Contract development and manufacturing organizations are responding by investing in local capacity and diversifying raw‐material portfolios. This recalibration is expected to streamline workflows and reduce reliance on single-source suppliers, even as industry players navigate the short‐term financial impact of tariff-induced cost pressures.

Key Insights from Market Segmentation Across Applications and Technologies

When organized by application, the clinical segment leads in complexity and revenue contribution, encompassing anesthetics, antibiotics, antivirals, cancer therapies, diabetes management agents and pain management drugs. Diagnostics platforms focus on biomarker monitoring, comprehensive blood tests and advanced imaging modalities, while research and development initiatives span genetic research, molecular biology studies and tissue engineering projects.

Technological segmentation reveals four dominant platforms: inorganic systems utilize gold nanoparticles, magnetic nanoparticles and silica nanoparticles to achieve targeted accumulation and triggered release; lipid-based systems deploy emulsions, liposomes and solid lipid nanoparticles to encapsulate a wide range of molecules; polymeric systems feature liposomes alongside microspheres and nanoparticles for controlled degradation profiles; and protein-based systems leverage antibodies and peptides for high-affinity targeting.

End-user segmentation highlights hospitals-both private and public-as principal adopters, with research centers in academic institutions and pharmaceutical research facilities driving preclinical innovation. Specialty clinics, including diabetic, oncology and pediatric practices, are increasingly incorporating targeted therapies into their treatment protocols.

Drug-type segmentation identifies biologicals such as antibodies, fusion proteins and vaccines alongside gene therapies differentiated by non‐viral and viral vectors. Monoclonal antibodies span chimeric, humanized and murine variants, while small molecule drugs focus on anti-inflammatories and pain relievers.

Carrier-type insights show hybrid carriers built on nanoemulsions and polysaccharide-based matrices, microcarriers composed of microparticles and polymeric micelles, and nanocarriers designed as dendrimers and liposomes. Administration route analysis covers inhalation via inhalers and nebulizers, intravenous delivery through infusions and injections, oral dosage forms such as capsules, pills and tablets, and topical applications including creams, gels and patches.

Finally, component-level segmentation differentiates active pharmaceutical ingredients sourced from natural and synthetic origins, alongside formulation excipients that include preservatives, solvents and stabilizers. This comprehensive segmentation framework underscores the intricate interplay of application, technology and user requirements driving innovation in targeted delivery.

Regional Dynamics Driving Growth and Innovation in Targeted Drug Delivery

Regional dynamics reveal distinct drivers of adoption and innovation across three major markets. In the Americas, robust research funding, established manufacturing infrastructure and progressive regulatory harmonization foster early adoption of advanced delivery platforms. North American centers of excellence and clinical trial networks accelerate translational research, while Latin American markets offer growth potential through expanding healthcare access.

In Europe, regulatory pathways are increasingly aligned under centralized agencies, supporting streamlined evaluations for nanoparticle-based therapies and complex biologics. The Middle East and Africa region, led by Gulf nations and South Africa, is investing in life sciences infrastructure, with public-private partnerships fueling capacity building and localized production.

Asia-Pacific is characterized by rapid market expansion, driven by favorable demographics, rising healthcare expenditure and strong government incentives for innovation. China and India are developing domestic nanoparticle manufacturing capabilities, while Japan and Australia continue to excel in high-precision formulation technologies. Collectively, these regions form a dynamic mosaic of demand, each requiring tailored strategies to address regulatory nuances, patient demographics and reimbursement landscapes.

Competitive Landscape and Profiles of Leading Industry Players

Competitive analysis highlights a diverse mix of global healthcare leaders, specialty biotech firms and emerging innovators shaping the sector. Established conglomerates such as 3M Company, Baxter International and Johnson & Johnson leverage extensive R&D pipelines and manufacturing scale to introduce next-generation carriers. Pharmaceutical giants including AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc. and Sanofi S.A. are integrating targeted delivery platforms into their oncology, immunology and metabolic disease portfolios.

Specialized companies such as Arrowhead Pharmaceuticals, Inc., Ocuphire Pharma, Inc. and Savara Inc. focus on niche therapeutic areas and novel vector designs, driving breakthroughs in genetic and pulmonary delivery. Device and diagnostics innovators like Becton, Dickinson and Company and Boston Scientific Corporation are collaborating on theranostic solutions that unite imaging with controlled release. Luye Pharma AG is advancing proprietary lipidic formulations, while Taiwan Liposome Company, Ltd. is recognized for its liposomal drug delivery expertise.

This competitive landscape underlines the importance of strategic alliances, co-development agreements and licensing deals. Organizations that combine specialized technology platforms with global commercialization networks are best positioned to deliver differentiated, regulatory-compliant therapies at scale.

Actionable Recommendations for Industry Leaders to Navigate Challenges and Capitalize on Opportunities

Leaders should prioritize investment in flexible manufacturing platforms capable of accommodating multiple carrier types and biologic formulations. Engaging regulatory authorities early through collaborative review programs can de-risk development pathways and shorten time to market. Forming cross-sector partnerships-linking material science experts, clinical research organizations and digital technology providers-will accelerate innovation cycles and optimize resource allocation.

Focusing on supply chain resilience by qualifying secondary suppliers and exploring regional production hubs will mitigate tariff-driven cost pressures. Incorporating real-world evidence generation and health economics assessments into commercialization plans will strengthen payer negotiations and facilitate market access. Finally, embedding patient-centric design principles into formulation development will enhance adherence, improve outcomes and build stakeholder trust.

Conclusion: Steering the Future of Targeted Drug Delivery

Targeted drug delivery systems occupy a pivotal role at the intersection of science, technology and patient care. As the field advances, success will depend on harmonizing regulatory agility, manufacturing excellence and cross-disciplinary collaboration. By embracing flexible development frameworks, resilient supply chains and data-driven insights, organizations can navigate evolving market dynamics and deliver transformative therapies.

The comprehensive segmentation, regional and competitive analyses presented herein offer a roadmap for identifying high-value opportunities and anticipating potential disruptions. Leaders who act decisively-integrating personalized medicine imperatives, supply chain optimization and stakeholder engagement-will set new benchmarks in therapeutic precision and patient impact.

Market Segmentation & Coverage

This research report categorizes the Targeted Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Clinical
    • Anesthetics
    • Antibiotics
    • Antivirals
    • Cancer Therapy
    • Diabetes Management
    • Pain Management
  • Diagnostics
    • Biomarker Monitoring
    • Blood Tests
    • Imaging
  • Research & Development
    • Genetic Research
    • Molecular Biology Studies
    • Tissue Engineering
  • Inorganic Systems
    • Gold Nanoparticles
    • Magnetic Nanoparticles
    • Silica Nanoparticles
  • Lipid-Based Systems
    • Emulsions
    • Liposomes
    • Solid Lipid Nanoparticles
  • Polymeric Systems
    • Liposomes
    • Microspheres
    • Nanoparticles
  • Protein-Based Systems
    • Antibodies
    • Peptides
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Centers
    • Academic Research Institutions
    • Pharmaceutical Research Centers
  • Specialty Clinics
    • Diabetic Clinics
    • Oncology Clinics
    • Pediatric Clinics
  • Biologicals
    • Antibodies
    • Fusion Proteins
    • Vaccines
  • Gene Therapy
    • Non-Viral Vectors
    • Viral Vectors
  • Monoclonal Antibodies
    • Chimeric
    • Humanized
    • Murine
  • Small Molecule Drugs
    • Anti-Inflammatories
    • Pain Relievers
  • Hybrid Carriers
    • Nanoemulsions
    • Polysaccharide-Based Carriers
  • Microcarriers
    • Microparticles
    • Polymeric Micelles
  • Nanocarriers
    • Dendrimers
    • Liposomes
  • Inhalation
    • Inhalers
    • Nebulizers
  • Intravenous
    • Infusions
    • Injections
  • Oral
    • Capsules
    • Pills
    • Tablets
  • Topical
    • Creams
    • Gels
    • Patches
  • Active Pharmaceutic Ingredients
    • Natural Sources
    • Synthetic
  • Formulation Excipients
    • Preservatives
    • Solvents
    • Stabilizers

This research report categorizes the Targeted Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Targeted Drug Delivery System Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 3M Company
  • AbbVie Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • LUYE PHARMA AG
  • Ocuphire Pharma, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Savara Inc.
  • Taiwan Liposome Company, Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Drug Delivery System Market, by Application
8.1. Introduction
8.2. Clinical
8.2.1. Anesthetics
8.2.2. Antibiotics
8.2.3. Antivirals
8.2.4. Cancer Therapy
8.2.5. Diabetes Management
8.2.6. Pain Management
8.3. Diagnostics
8.3.1. Biomarker Monitoring
8.3.2. Blood Tests
8.3.3. Imaging
8.4. Research & Development
8.4.1. Genetic Research
8.4.2. Molecular Biology Studies
8.4.3. Tissue Engineering
9. Targeted Drug Delivery System Market, by Technology
9.1. Introduction
9.2. Inorganic Systems
9.2.1. Gold Nanoparticles
9.2.2. Magnetic Nanoparticles
9.2.3. Silica Nanoparticles
9.3. Lipid-Based Systems
9.3.1. Emulsions
9.3.2. Liposomes
9.3.3. Solid Lipid Nanoparticles
9.4. Polymeric Systems
9.4.1. Liposomes
9.4.2. Microspheres
9.4.3. Nanoparticles
9.5. Protein-Based Systems
9.5.1. Antibodies
9.5.2. Peptides
10. Targeted Drug Delivery System Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Research Centers
10.3.1. Academic Research Institutions
10.3.2. Pharmaceutical Research Centers
10.4. Specialty Clinics
10.4.1. Diabetic Clinics
10.4.2. Oncology Clinics
10.4.3. Pediatric Clinics
11. Targeted Drug Delivery System Market, by Drug Type
11.1. Introduction
11.2. Biologicals
11.2.1. Antibodies
11.2.2. Fusion Proteins
11.2.3. Vaccines
11.3. Gene Therapy
11.3.1. Non-Viral Vectors
11.3.2. Viral Vectors
11.4. Monoclonal Antibodies
11.4.1. Chimeric
11.4.2. Humanized
11.4.3. Murine
11.5. Small Molecule Drugs
11.5.1. Anti-Inflammatories
11.5.2. Pain Relievers
12. Targeted Drug Delivery System Market, by Carrier Type
12.1. Introduction
12.2. Hybrid Carriers
12.2.1. Nanoemulsions
12.2.2. Polysaccharide-Based Carriers
12.3. Microcarriers
12.3.1. Microparticles
12.3.2. Polymeric Micelles
12.4. Nanocarriers
12.4.1. Dendrimers
12.4.2. Liposomes
13. Targeted Drug Delivery System Market, by Administration Route
13.1. Introduction
13.2. Inhalation
13.2.1. Inhalers
13.2.2. Nebulizers
13.3. Intravenous
13.3.1. Infusions
13.3.2. Injections
13.4. Oral
13.4.1. Capsules
13.4.2. Pills
13.4.3. Tablets
13.5. Topical
13.5.1. Creams
13.5.2. Gels
13.5.3. Patches
14. Targeted Drug Delivery System Market, by Component
14.1. Introduction
14.2. Active Pharmaceutic Ingredients
14.2.1. Natural Sources
14.2.2. Synthetic
14.3. Formulation Excipients
14.3.1. Preservatives
14.3.2. Solvents
14.3.3. Stabilizers
15. Americas Targeted Drug Delivery System Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Targeted Drug Delivery System Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Targeted Drug Delivery System Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. 3M Company
18.3.2. AbbVie Inc.
18.3.3. Arrowhead Pharmaceuticals, Inc.
18.3.4. AstraZeneca PLC
18.3.5. Baxter International Inc.
18.3.6. Becton, Dickinson and Company
18.3.7. Boston Scientific Corporation
18.3.8. F. Hoffmann-La Roche Ltd
18.3.9. Johnson & Johnson Services, Inc.
18.3.10. LUYE PHARMA AG
18.3.11. Ocuphire Pharma, Inc.
18.3.12. Pfizer Inc.
18.3.13. Sanofi S.A.
18.3.14. Savara Inc.
18.3.15. Taiwan Liposome Company, Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TARGETED DRUG DELIVERY SYSTEM MARKET MULTI-CURRENCY
FIGURE 2. TARGETED DRUG DELIVERY SYSTEM MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TARGETED DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TARGETED DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOMARKER MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MOLECULAR BIOLOGY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MAGNETIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SILICA NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PHARMACEUTICAL RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIABETIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEDIATRIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYSACCHARIDE-BASED CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INFUSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PILLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 107. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 108. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 109. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 110. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 111. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 112. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NATURAL SOURCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 113. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 114. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 115. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 116. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 117. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLVENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 118. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 119. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 135. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 136. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 138. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 139. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 140. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 141. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 142. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 144. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 145. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 146. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 147. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 148. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 149. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 150. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 208. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 209. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 210. BRAZIL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 211. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 213. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 214. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 215. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 217. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 218. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 219. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 220. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 223. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 224. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 226. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 227. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 228. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 229. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 230. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 231. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 232. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 233. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 234. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 235. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 236. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 237. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 238. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 239. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 240. CANADA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 241. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 243. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 244. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 245. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 247. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 248. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 249. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 250. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 253. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 255. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 256. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 257. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 259. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 260. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 261. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 262. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 263. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 264. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 265. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 266. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 267. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 268. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 269. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 270. MEXICO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 271. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 273. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 274. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 275. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INORGANIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 277. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPID-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 278. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY POLYMERIC SYSTEMS, 2018-2030 (USD MILLION)
TABLE 279. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PROTEIN-BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 280. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 283. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 284. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 285. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICALS, 2018-2030 (USD MILLION)
TABLE 286. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 287. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 288. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 289. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARRIER TYPE, 2018-2030 (USD MILLION)
TABLE 290. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HYBRID CARRIERS, 2018-2030 (USD MILLION)
TABLE 291. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROCARRIERS, 2018-2030 (USD MILLION)
TABLE 292. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOCARRIERS, 2018-2030 (USD MILLION)
TABLE 293. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 294. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 295. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 296. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 298. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 299. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ACTIVE PHARMACEUTIC INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 300. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION EXCIPIENTS, 2018-2030 (USD MILLION)
TABLE 301. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE

Companies Mentioned

  • 3M Company
  • AbbVie Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • LUYE PHARMA AG
  • Ocuphire Pharma, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Savara Inc.
  • Taiwan Liposome Company, Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Drug Delivery Systems Market - Global Forecast to 2030 - Product Image

Drug Delivery Systems Market - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode of Delivery, Application, End User - Global Forecast 2025-2030 - Product Image

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode of Delivery, Application, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast - Product Image

Targeted Drug Delivery Device Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area, Key Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 275 Pages
  • Global
From
Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report - Product Image

Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report

  • Report
  • 492 Pages
  • Global
From
Targeted Drug Delivery System Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Targeted Drug Delivery System Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 98 Pages
  • Global
From

About the Targeted Drug Delivery System Market

Targeted Drug Delivery System (TDDS) is a specialized area within the broader pharmacological field of Drug Delivery. TDDS aims to direct medication to specific cells, tissues, or organs, thereby increasing the concentration of the drug at the intended site of action while minimizing its presence in the rest of the body. This method potentially reduces side effects and enhances treatment efficacy. The market for these systems encompasses a wide range of technologies and platforms, such as nanoparticles, liposomes, and biodegradable polymers designed to release pharmaceutical compounds in a controlled manner. The field has been propelled by advances in biotechnology, nanotechnology, and molecular biology, which have contributed to the development of novel targeted drug delivery mechanisms. These include antibodies, receptor-mediated delivery systems, and gene-delivery vectors. TDDS is used in addressing various medical conditions, with cancer therapy being a particularly active area due to the need for precise drug delivery to tumor cells. Several companies specialize in the research and development of Targeted Drug Delivery Systems, contributing to the maturation of this market. Some notable players in the field include Alkermes, BIND Therapeutics, DEPArray Technology, Genentech, Immunomedics, Inc., and Kite Pharma. These companies have a diverse product portfolio of targeted delivery technologies and are engaged in the development of innovative treatments for a wide range of diseases, striving to improve therapeutic outcomes and patient quality of life. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.